Mesenchymal stem cell explained

Mesenchymal stem cell
Latin:cellula mesenchymatica praecursoria

Mesenchymal stem cells (MSCs) also known as mesenchymal stromal cells or medicinal signaling cells, are multipotent stromal cells that can differentiate into a variety of cell types, including osteoblasts (bone cells), chondrocytes (cartilage cells), myocytes (muscle cells) and adipocytes (fat cells which give rise to marrow adipose tissue).[1] [2] [3] [4]

Structure

Definition

Mesenchymal stem cells (MSCs), a term first named (1991) by Arnold I. Caplan at Case Western Reserve University,[5] are characterized morphologically by a small cell body with a few cell processes that are long and thin. While the terms mesenchymal stem cell (MSC) and marrow stromal cell have been used interchangeably for many years, neither term is sufficiently descriptive:

Morphology

The cell body contains a large, round nucleus with a prominent nucleolus, which is surrounded by finely dispersed chromatin particles, giving the nucleus a clear appearance. The remainder of the cell body contains a small amount of Golgi apparatus, rough endoplasmic reticulum, mitochondria, and polyribosomes. The cells, which are long and thin, are widely dispersed, and the adjacent extracellular matrix is populated by a few reticular fibrils, but is devoid of the other types of collagen fibrils.[11] [12] These distinctive morphological features of mesenchymal stem cells can be visualized label-free using live cell imaging.

Classification

The International Society for Cellular Therapy (ISCT) has proposed a set of standards to define MSCs. A cell can be classified as an MSC if it shows plastic adherent properties under normal culture conditions and has a fibroblast-like morphology. In fact, some argue that MSCs and fibroblasts are functionally identical.[13] The study in Science, "Multilineage Potential of Adult Mesenchymal Stem Cells," describe how MSCs can undergo osteogenic, adipogenic and chondrogenic differentiation ex vivo. As of November 2023, this paper has been cited over 29,000 times. The cultured MSCs also express on their surface CD73, CD90 and CD105, while lacking the expression of CD11b, CD14, CD19, CD34, CD45, CD79a and HLA-DR surface markers.[14]

Location in the body

MSCs are found throughout the human body.

Bone marrow

Bone marrow was the original source of MSCs,[15] and is still the most frequently utilized source. These bone marrow stem cells do not contribute to the formation of blood cells, and so do not express the hematopoietic stem cell marker CD34. They are sometimes referred to as bone marrow stromal stem cells.[16]

Cord cells

The youngest and most primitive MSCs may be obtained from umbilical cord tissue, namely Wharton's jelly and the umbilical cord blood. However, MSCs are found in much higher concentration in the Wharton's jelly compared to cord blood, which is a rich source of hematopoietic stem cells. The umbilical cord is available after a birth. It is normally discarded, and poses no risk for collection. These MSCs may prove to be a useful source of MSCs for clinical applications, due to their primitive properties and fast growth rate.[17]

Adipose tissue

Adipose-tissue-derived MSCs (AdMSCs), in addition to being easier and safer to isolate than bone-marrow-derived MSCs, can be obtained in larger quantities.[18]

Molar cells

The developing tooth bud of the mandibular third molar is a rich source of MSCs. While they are described as multipotent, it is possible that they are pluripotent. They eventually form enamel, dentin, blood vessels, dental pulp, and nervous tissues. These stem cells are capable of differentiating into chondrocytes, cardiomyocytes, melanocytes, and hepatocyte‐like cells in vitro.

Amniotic fluid

Stem cells are present in amniotic fluid. As many as 1 in 100 cells collected during amniocentesis are pluripotent mesenchymal stem cells.[19]

Function

Differentiation capacity

MSCs have a great capacity for self-renewal while maintaining their multipotency. Recent work suggests that β-catenin, via regulation of EZH2, is a central molecule in maintaining the "stemness" of MSC's.[20] The standard test to confirm multipotency is differentiation of the cells into osteoblasts, adipocytes and chondrocytes as well as myocytes.

MSCs have been seen to even differentiate into neuron-like cells,[21] but doubt remains about whether the MSC-derived neurons are functional.[22] The degree to which the culture will differentiate varies among individuals and how differentiation is induced, e.g., chemical vs. mechanical;[23] and it is not clear whether this variation is due to a different amount of "true" progenitor cells in the culture or variable differentiation capacities of individuals' progenitors. The capacity of cells to proliferate and differentiate is known to decrease with the age of the donor, as well as the time in culture.[24] Likewise, whether this is due to a decrease in the number of MSCs or a change to the existing MSCs is not known.

Immunomodulatory effects

MSCs have an effect on innate and specific immune cells, and research has shown an ability to suppress tumor growth.[25] MSCs produce many immunomodulatory molecules including prostaglandin E2 (PGE2),[26] nitric oxide,[27] indoleamine 2,3-dioxygenase (IDO), interleukin 6 (IL-6), and other surface markers such as FasL,[28] PD-L1 and PD-L2.[29]

MSCs have an effect on macrophages, neutrophils, NK cells, mast cells and dendritic cells in innate immunity. MSCs are able to migrate to the site of injury, where they polarize through PGE2 macrophages in M2 phenotype which is characterized by an anti-inflammatory effect.[30] Further, PGE2 inhibits the ability of mast cells to degranulate and produce TNF-α.[31] [32] Proliferation and cytotoxic activity of NK cells is inhibited by PGE2 and IDO. MSCs also reduce the expression of NK cell receptors - NKG2D, NKp44 and NKp30.[33] MSCs inhibit respiratory flare and apoptosis of neutrophils by production of cytokines IL-6 and IL-8.[34] Differentiation and expression of dendritic cell surface markers is inhibited by IL-6 and PGE2 of MSCs.[35] The immunosuppressive effects of MSC also depend on IL-10, but it is not certain whether they produce it alone, or only stimulate other cells to produce it.[36]

MSC expresses the adhesion molecules VCAM-1 and ICAM-1, which allow T-lymphocytes to adhere to their surface. Then MSC can affect them by molecules which have a short half-life and their effect is in the immediate vicinity of the cell.[27] These include nitric oxide,[37] PGE2, HGF,[38] and activation of receptor PD-1.[39] MSCs reduce T cell proliferation between G0 and G1 cell cycle phases[40] and decrease the expression of IFNγ of Th1 cells while increasing the expression of IL-4 of Th2 cells.[41] MSCs also inhibit the proliferation of B-lymphocytes between G0 and G1 cell cycle phases.[39] [42]

Antimicrobial properties

MSCs produce several antimicrobial peptides (AMPs) including human cathelicidin LL-37,[43] β-defensins,[44] lipocalin 2[45] and hepcidin.[46] These peptides, together with the enzyme indoleamine 2,3-dioxygenase (IDO), are responsible for the broad-spectrum antibacterial activity of MSCs.[47]

Clinical significance

See also: Clinical uses of mesenchymal stem cells. Mesenchymal stem cells can be activated and mobilized in reaction to injury and infection. As of May 2024, a search for "mesenchymal stem cells" or "mesenchymal stromal cells" at ClinicalTrials.gov returns more than 1,760 studies featuring MSCs[48] for more than 920 conditions.

Autoimmune disease

Clinical studies investigating the efficacy of mesenchymal stem cells in treating diseases are in clinical development around the world, particularly treating autoimmune diseases, graft versus host disease, Crohn's disease, multiple sclerosis, systemic lupus erythematosus and systemic sclerosis.[49] [50]

Other diseases

Many of the early clinical successes using intravenous transplantation came in systemic diseases such as graft versus host disease and sepsis. Direct injection or placement of cells into a site in need of repair may be the preferred method of treatment, as vascular delivery suffers from a "pulmonary first pass effect" where intravenous injected cells are sequestered in the lungs.[51]

Further studies into the mechanisms of MSC action may provide avenues for increasing their capacity for tissue repair.[52] [53]

Research

The majority of modern culture techniques still take a colony-forming unit-fibroblasts (CFU-F) approach, where raw unpurified bone marrow or ficoll-purified bone marrow mononuclear cells are plated directly into cell culture plates or flasks. Mesenchymal stem cells, but not red blood cells or hematopoietic progenitors, are adherent to tissue culture plastic within 24 to 48 hours. However, at least one publication has identified a population of non-adherent MSCs that are not obtained by the direct-plating technique.[54]

Other flow cytometry-based methods allow the sorting of bone marrow cells for specific surface markers, such as STRO-1.[55] STRO-1+ cells are generally more homogenous and have higher rates of adherence and higher rates of proliferation, but the exact differences between STRO-1+ cells and MSCs are not clear.[56]

Methods of immunodepletion using such techniques as MACS have also been used in the negative selection of MSCs.[57]

The supplementation of basal media with fetal bovine serum or human platelet lysate is common in MSC culture. Prior to the use of platelet lysates for MSC culture, the pathogen inactivation process is recommended to prevent pathogen transmission.[58]

New research titled Transplantation of human ESC-derived mesenchymal stem cell spheroids ameliorates spontaneous osteoarthritis in rhesus macaques[59] Various chemicals and methods including low level laser irradiation have been used to increase proliferation of stem cell.[60]

History

Scientists Ernest A. McCulloch and James E. Till first revealed the clonal nature of marrow cells in the 1960s.[61] [62] In 1970, Arnold Caplan identified certain conditions by which mesodermal cells differentiate into cartilage or myogenic (muscle) tissue and bone.[63]

An ex vivo assay for examining the clonogenic potential of multipotent marrow cells was later reported in the 1970s by Friedenstein and colleagues.[64] [65] In this assay system, stromal cells were referred to as colony-forming unit-fibroblasts (CFU-f).

Subsequent experimentation revealed the plasticity of marrow cells and how their fate is determined by environmental cues. Culturing marrow stromal cells in the presence of osteogenic stimuli such as ascorbic acid, inorganic phosphate and dexamethasone could promote their differentiation into osteoblasts. In contrast, the addition of transforming growth factor-beta (TGF-b) could induce chondrogenic markers.

The first clinical trials of MSCs were completed by Osiris Therapeutics in 1995 when a group of 15 patients were injected with cultured MSCs to test the safety of the treatment.[66] The first regulatory approvals for MSCs were granted conditional approval in 2012 in Canada and New Zealand for treating Graft vs. Host Disease (GvHD) and, subsequently, in Japan to treat Crohn’s Disease-related fistula.[67]

Since then, more than 1,000 clinical trials have been conducted to treat numerous conditions.[68]

Controversies

The term "mesenchymal stem cells" and what constitutes the most scientifically correct meaning for the MSC initialism, has been debated for years. Most mesenchymal cell or "MSC" preps only contain a minority fraction of true multipotent stem cells, with most cells being stromal in nature. Caplan proposed rephrasing MSCs to emphasize their role as "medicinal signaling cells."[69] Within the stem cell field, the shorthand "MSC" has most commonly now come to refer to "mesenchymal stromal/stem cells" because of the heterogeneous nature of the cellular preparations.

There is also growing concern about the marketing and application of unapproved MSCs and mesenchymal stem cells that lack rigorous data to back up these clinical uses into patients by for-profit clinics.[70] [71]

See also

Further reading

External links

Notes and References

  1. Book: Tonk CH, Witzler M, Schulze M, Tobiasch E . Mesenchymal Stem Cells. 2020. Essential Current Concepts in Stem Cell Biology. 21–39. Brand-Saberi B . Learning Materials in Biosciences. Cham. Springer International Publishing . en . 10.1007/978-3-030-33923-4_2. 978-3-030-33923-4 . 214523766 .
  2. Ankrum JA, Ong JF, Karp JM . Mesenchymal stem cells: immune evasive, not immune privileged . Nature Biotechnology . 32 . 3 . 252–60 . March 2014 . 24561556 . 4320647 . 10.1038/nbt.2816 .
  3. Mahla RS . Stem Cells Applications in Regenerative Medicine and Disease Therapeutics . International Journal of Cell Biology . 2016 . 6940283 . 2016 . 27516776 . 4969512 . 10.1155/2016/6940283 . free .
  4. Caplan AI . Mesenchymal Stem Cells: Time to Change the Name! . Stem Cells Translational Medicine . 6 . 6 . 1445–1451 . June 2017 . 28452204 . 5689741 . 10.1002/sctm.17-0051 .
  5. Bianco P, Robey PG, Simmons PJ . April 2008 . Mesenchymal stem cells: revisiting history, concepts, and assays . Cell Stem Cell . 2 . 4 . 313–319 . 10.1016/j.stem.2008.03.002 . 2613570 . 18397751.
  6. Porcellini A . Regenerative medicine: a review . Revista Brasileira de Hematologia e Hemoterapia . 2009 . 31 . Suppl. 2 . 10.1590/S1516-84842009000800017 . free .
  7. Valero MC, Huntsman HD, Liu J, Zou K, Boppart MD . Eccentric exercise facilitates mesenchymal stem cell appearance in skeletal muscle . PLOS ONE . 7 . 1 . e29760 . 2012 . 22253772 . 3256189 . 10.1371/journal.pone.0029760 . 2012PLoSO...729760V . free .
  8. Wang S, Qu X, Zhao RC . Clinical applications of mesenchymal stem cells . Journal of Hematology & Oncology . 5 . 19 . April 2012 . 22546280 . 3416655 . 10.1186/1756-8722-5-19 . free .
  9. Branch MJ, Hashmani K, Dhillon P, Jones DR, Dua HS, Hopkinson A . Mesenchymal stem cells in the human corneal limbal stroma . Investigative Ophthalmology & Visual Science . 53 . 9 . 5109–16 . August 2012 . 22736610 . 10.1167/iovs.11-8673 .
  10. Liu J, Yu F, Sun Y, Jiang B, Zhang W, Yang J, Xu G, Liang A, Liu S . March 2015 . Concise Reviews: Characteristics and Potential Applications of Human Dental Tissue-Derived Mesenchymal Stem Cells . Stem Cells . 33 . 3 . 627–38 . 10.1002/stem.1909 . 25447379 . free.
  11. Book: Netter FH . Frank H. Netter . 1987 . Musculoskeletal system: anatomy, physiology, and metabolic disorders . Summit, New Jersey . Ciba-Geigy Corporation . 978-0-914168-88-1 . 134.
  12. Brighton CT, Hunt RM . Early histological and ultrastructural changes in medullary fracture callus . The Journal of Bone and Joint Surgery. American Volume . 73 . 6 . 832–847 . July 1991 . 2071617 . 10.2106/00004623-199173060-00006 .
  13. Hematti P . May 2012 . Mesenchymal stromal cells and fibroblasts: a case of mistaken identity? . Cytotherapy . 14 . 5 . 516–21 . 10.3109/14653249.2012.677822 . 22458957.
  14. 6 . Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, Deans R, Keating A, Prockop D, Horwitz E . 1 January 2006 . Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement . Cytotherapy . 8 . 4 . 315–7 . 10.1080/14653240600855905 . 16923606.
  15. Strioga M, Viswanathan S, Darinskas A, Slaby O, Michalek J . September 2012 . Same or Not the Same? Comparison of Adipose Tissue-Derived Versus Bone Marrow-Derived Mesenchymal Stem and Stromal Cells. Stem Cells and Development . 21 . 14 . 2724–52 . 10.1089/scd.2011.0722 . 22468918.
  16. Gregory CA, Prockop DJ, Spees JL . Non-hematopoietic bone marrow stem cells: molecular control of expansion and differentiation . Experimental Cell Research . 306 . 2 . 330–5 . June 2005 . 15925588 . 10.1016/j.yexcr.2005.03.018 . Molecular Control of Stem Cell Differentiation .
  17. Liau LL, Ruszymah BH, Ng MH, Law JX . Jan 2020 . Characteristics and Clinical Applications of Wharton's Jelly-Derived Mesenchymal Stromal Cells . Current Research in Translational Medicine . 68 . 1 . 5–16 . 10.1016/j.retram.2019.09.001 . 31543433 . 202731274 .
  18. Bunnell BA, Flaat M, Gagliardi C, Patel B, Ripoll C . Adipose-derived stem cells: isolation, expansion and differentiation . Methods . 45 . 2 . 115–20 . June 2008 . 18593609 . 3668445 . 10.1016/j.ymeth.2008.03.006 . Methods in stem cell research .
  19. Web site: What is Cord Tissue?. CordAdvantage.com. 2018-10-30.
  20. Sen B, Paradise CR, Xie Z, Sankaran J, Uzer G, Styner M, Meyer M, Dudakovic A, van Wijnen AJ, Rubin J . 6 . β-Catenin Preserves the Stem State of Murine Bone Marrow Stromal Cells Through Activation of EZH2 . Journal of Bone and Mineral Research . 35 . 6 . 1149–1162 . June 2020 . 32022326 . 7295671 . 10.1002/jbmr.3975 . free .
  21. Jiang Y, Jahagirdar BN, Reinhardt RL, Schwartz RE, Keene CD, Ortiz-Gonzalez XR, Reyes M, Lenvik T, Lund T, Blackstad M, Du J, Aldrich S, Lisberg A, Low WC, Largaespada DA, Verfaillie CM . 6 . Pluripotency of mesenchymal stem cells derived from adult marrow . Nature . 418 . 6893 . 41–9 . July 2002 . 12077603 . 10.1038/nature00870 . 2002Natur.418...41J . 47162269 .
  22. Franco Lambert AP, Fraga Zandonai A, Bonatto D, Cantarelli Machado D, Pêgas Henriques JA . Differentiation of human adipose-derived adult stem cells into neuronal tissue: does it work? . Differentiation; Research in Biological Diversity . 77 . 3 . 221–8 . March 2009 . 19272520 . 10.1016/j.diff.2008.10.016 .
  23. Engler AJ, Sen S, Sweeney HL, Discher DE . Matrix elasticity directs stem cell lineage specification . Cell . 126 . 4 . 677–89 . August 2006 . 16923388 . 10.1016/j.cell.2006.06.044 . 16109483 . free .
  24. Choudhery MS, Badowski M, Muise A, Pierce J, Harris DT . Donor age negatively impacts adipose tissue-derived mesenchymal stem cell expansion and differentiation . Journal of Translational Medicine . 12 . 1 . 8 . January 2014 . 24397850 . 3895760 . 10.1186/1479-5876-12-8 . free .
  25. Banerjee K, Chattopadhyay A, Banerjee S . July 2022 . Understanding the association of stem cells in fetal development and carcinogenesis during pregnancy . Advances in Cancer Biology - Metastasis . en . 4 . 100042 . 10.1016/j.adcanc.2022.100042 . 248485831 . 2667-3940. free .
  26. Spaggiari GM, Abdelrazik H, Becchetti F, Moretta L . MSCs inhibit monocyte-derived DC maturation and function by selectively interfering with the generation of immature DCs: central role of MSC-derived prostaglandin E2 . Blood . 113 . 26 . 6576–6583 . June 2009 . 19398717 . 10.1182/blood-2009-02-203943 . 206878089 . free .
  27. Ren G, Zhao X, Zhang L, Zhang J, L'Huillier A, Ling W, Roberts AI, Le AD, Shi S, Shao C, Shi Y . 6 . Inflammatory cytokine-induced intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 in mesenchymal stem cells are critical for immunosuppression . Journal of Immunology . 184 . 5 . 2321–2328 . March 2010 . 20130212 . 2881946 . 10.4049/jimmunol.0902023 .
  28. Akiyama K, Chen C, Wang D, Xu X, Qu C, Yamaza T, Cai T, Chen W, Sun L, Shi S . 6 . Mesenchymal-stem-cell-induced immunoregulation involves FAS-ligand-/FAS-mediated T cell apoptosis . Cell Stem Cell . 10 . 5 . 544–555 . May 2012 . 22542159 . 3348385 . 10.1016/j.stem.2012.03.007 .
  29. Davies LC, Heldring N, Kadri N, Le Blanc K . Mesenchymal Stromal Cell Secretion of Programmed Death-1 Ligands Regulates T Cell Mediated Immunosuppression . Stem Cells . 35 . 3 . 766–776 . March 2017 . 27671847 . 5599995 . 10.1002/stem.2509 .
  30. Kim J, Hematti P . Mesenchymal stem cell-educated macrophages: a novel type of alternatively activated macrophages . Experimental Hematology . 37 . 12 . 1445–53 . December 2009 . 19772890 . 2783735 . 10.1016/j.exphem.2009.09.004 .
  31. Brown JM, Nemeth K, Kushnir-Sukhov NM, Metcalfe DD, Mezey E . Bone marrow stromal cells inhibit mast cell function via a COX2-dependent mechanism . Clinical and Experimental Allergy . 41 . 4 . 526–34 . April 2011 . 21255158 . 3078050 . 10.1111/j.1365-2222.2010.03685.x .
  32. Kay LJ, Yeo WW, Peachell PT . Prostaglandin E2 activates EP2 receptors to inhibit human lung mast cell degranulation . British Journal of Pharmacology . 147 . 7 . 707–13 . April 2006 . 16432506 . 1751511 . 10.1038/sj.bjp.0706664 .
  33. Spaggiari GM, Capobianco A, Becchetti S, Mingari MC, Moretta L . Mesenchymal stem cell-natural killer cell interactions: evidence that activated NK cells are capable of killing MSCs, whereas MSCs can inhibit IL-2-induced NK-cell proliferation . Blood . 107 . 4 . 1484–90 . February 2006 . 16239427 . 10.1182/blood-2005-07-2775 . 11567/267587 . free .
  34. Raffaghello L, Bianchi G, Bertolotto M, Montecucco F, Busca A, Dallegri F, Ottonello L, Pistoia V . 6 . Human mesenchymal stem cells inhibit neutrophil apoptosis: a model for neutrophil preservation in the bone marrow niche . Stem Cells . 26 . 1 . 151–62 . January 2008 . 17932421 . 10.1634/stemcells.2007-0416 . 32230553 . free .
  35. Jiang XX, Zhang Y, Liu B, Zhang SX, Wu Y, Yu XD, Mao N . Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells . Blood . 105 . 10 . 4120–6 . May 2005 . 15692068 . 10.1182/blood-2004-02-0586 . free .
  36. Ma S, Xie N, Li W, Yuan B, Shi Y, Wang Y . Immunobiology of mesenchymal stem cells . Cell Death and Differentiation . 21 . 2 . 216–25 . February 2014 . 24185619 . 3890955 . 10.1038/cdd.2013.158 .
  37. Ren G, Zhang L, Zhao X, Xu G, Zhang Y, Roberts AI, Zhao RC, Shi Y . 6 . Mesenchymal stem cell-mediated immunosuppression occurs via concerted action of chemokines and nitric oxide . Cell Stem Cell . 2 . 2 . 141–50 . February 2008 . 18371435 . 10.1016/j.stem.2007.11.014 . free .
  38. Di Nicola M, Carlo-Stella C, Magni M, Milanesi M, Longoni PD, Matteucci P, Grisanti S, Gianni AM . 6 . Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli . Blood . 99 . 10 . 3838–43 . May 2002 . 11986244 . 10.1182/blood.v99.10.3838 . 5889200 . free . 11379/598065 . free .
  39. Augello A, Tasso R, Negrini SM, Amateis A, Indiveri F, Cancedda R, Pennesi G . Bone marrow mesenchymal progenitor cells inhibit lymphocyte proliferation by activation of the programmed death 1 pathway . European Journal of Immunology . 35 . 5 . 1482–90 . May 2005 . 15827960 . 10.1002/eji.200425405 . 24088675 . free .
  40. Glennie S, Soeiro I, Dyson PJ, Lam EW, Dazzi F . Bone marrow mesenchymal stem cells induce division arrest anergy of activated T cells . Blood . 105 . 7 . 2821–7 . April 2005 . 15591115 . 10.1182/blood-2004-09-3696 . 33590543 . free .
  41. Aggarwal S, Pittenger MF . Human mesenchymal stem cells modulate allogeneic immune cell responses . Blood . 105 . 4 . 1815–22 . February 2005 . 15494428 . 10.1182/blood-2004-04-1559 . free .
  42. Corcione A, Benvenuto F, Ferretti E, Giunti D, Cappiello V, Cazzanti F, Risso M, Gualandi F, Mancardi GL, Pistoia V, Uccelli A . 6 . Human mesenchymal stem cells modulate B-cell functions . Blood . 107 . 1 . 367–72 . January 2006 . 16141348 . 10.1182/blood-2005-07-2657 . free .
  43. Krasnodembskaya A, Song Y, Fang X, Gupta N, Serikov V, Lee JW, Matthay MA . Antibacterial effect of human mesenchymal stem cells is mediated in part from secretion of the antimicrobial peptide LL-37 . Stem Cells . 28 . 12 . 2229–38 . December 2010 . 20945332 . 3293245 . 10.1002/stem.544 .
  44. Sung DK, Chang YS, Sung SI, Yoo HS, Ahn SY, Park WS . Antibacterial effect of mesenchymal stem cells against Escherichia coli is mediated by secretion of beta- defensin- 2 via toll- like receptor 4 signalling . Cellular Microbiology . 18 . 3 . 424–36 . March 2016 . 26350435 . 5057339 . 10.1111/cmi.12522 .
  45. Gupta N, Krasnodembskaya A, Kapetanaki M, Mouded M, Tan X, Serikov V, Matthay MA . Mesenchymal stem cells enhance survival and bacterial clearance in murine Escherichia coli pneumonia . Thorax . 67 . 6 . 533–9 . June 2012 . 22250097 . 3358432 . 10.1136/thoraxjnl-2011-201176 .
  46. Alcayaga-Miranda F, Cuenca J, Martin A, Contreras L, Figueroa FE, Khoury M . Combination therapy of menstrual derived mesenchymal stem cells and antibiotics ameliorates survival in sepsis . Stem Cell Research & Therapy . 6 . 199 . October 2015 . 26474552 . 4609164 . 10.1186/s13287-015-0192-0 . free .
  47. Meisel R, Brockers S, Heseler K, Degistirici O, Bülle H, Woite C, Stuhlsatz S, Schwippert W, Jäger M, Sorg R, Henschler R, Seissler J, Dilloo D, Däubener W . 6 . Human but not murine multipotent mesenchymal stromal cells exhibit broad-spectrum antimicrobial effector function mediated by indoleamine 2,3-dioxygenase . Leukemia . 25 . 4 . 648–54 . April 2011 . 21242993 . 10.1038/leu.2010.310 . free .
  48. Web site: Search of: Mesenchymal stem cells - List Results - ClinicalTrials.gov . 2023-05-26 . clinicaltrials.gov . en.
  49. Figueroa FE, Carrión F, Villanueva S, Khoury M . Mesenchymal stem cell treatment for autoimmune diseases: a critical review . Biological Research . 45 . 3 . 269–77 . 2012 . 23283436 . 10.4067/S0716-97602012000300008 . free .
  50. Sharma RR, Pollock K, Hubel A, McKenna D . Mesenchymal stem or stromal cells: a review of clinical applications and manufacturing practices . Transfusion . 54 . 5 . 1418–37 . May 2014 . 24898458 . 6364749 . 10.1111/trf.12421 .
  51. Fischer UM, Harting MT, Jimenez F, Monzon-Posadas WO, Xue H, Savitz SI, Laine GA, Cox CS . 6 . Pulmonary passage is a major obstacle for intravenous stem cell delivery: the pulmonary first-pass effect . Stem Cells and Development . 18 . 5 . 683–92 . June 2009 . 19099374 . 3190292 . 10.1089/scd.2008.0253 .
  52. Heirani-Tabasi A, Hassanzadeh M, Hemmati-Sadeghi S, Shahriyari M, Raeesolmohaddeseen M . 2015 . Mesenchymal Stem Cells; Defining the Future of Regenerative Medicine . Journal of Genes and Cells . 1 . 2 . 34–39 . 10.15562/gnc.15 . 87157970.
  53. 6 . Anderson JD, Johansson HJ, Graham CS, Vesterlund M, Pham MT, Bramlett CS, Montgomery EN, Mellema MS, Bardini RL, Contreras Z, Hoon M, Bauer G, Fink KD, Fury B, Hendrix KJ, Chedin F, El-Andaloussi S, Hwang B, Mulligan MS, Lehtiö J, Nolta JA . March 2016 . Comprehensive Proteomic Analysis of Mesenchymal Stem Cell Exosomes Reveals Modulation of Angiogenesis via Nuclear Factor-KappaB Signaling . Stem Cells . 34 . 3 . 601–13 . 10.1002/stem.2298 . 5785927 . 26782178.
  54. Wan C, He Q, McCaigue M, Marsh D, Li G . Nonadherent cell population of human marrow culture is a complementary source of mesenchymal stem cells (MSCs) . Journal of Orthopaedic Research . 24 . 1 . 21–8 . January 2006 . 16419965 . 10.1002/jor.20023 . 28963721 .
  55. Gronthos S, Graves SE, Ohta S, Simmons PJ . The STRO-1+ fraction of adult human bone marrow contains the osteogenic precursors . Blood . 84 . 12 . 4164–73 . December 1994 . 7994030 . 10.1182/blood.V84.12.4164.bloodjournal84124164 . free .
  56. Oyajobi BO, Lomri A, Hott M, Marie PJ . Isolation and characterization of human clonogenic osteoblast progenitors immunoselected from fetal bone marrow stroma using STRO-1 monoclonal antibody . Journal of Bone and Mineral Research . 14 . 3 . 351–61 . March 1999 . 10027900 . 10.1359/jbmr.1999.14.3.351 . 23683884 . free .
  57. Tondreau T, Lagneaux L, Dejeneffe M, Delforge A, Massy M, Mortier C, Bron D . Isolation of BM mesenchymal stem cells by plastic adhesion or negative selection: phenotype, proliferation kinetics and differentiation potential . Cytotherapy . 6 . 4 . 372–9 . 1 January 2004 . 16146890 . 10.1080/14653240410004943 .
  58. Iudicone P, Fioravanti D, Bonanno G, Miceli M, Lavorino C, Totta P, Frati L, Nuti M, Pierelli L . 6 . Pathogen-free, plasma-poor platelet lysate and expansion of human mesenchymal stem cells . Journal of Translational Medicine . 12 . 28 . January 2014 . 24467837 . 3918216 . 10.1186/1479-5876-12-28 . free .
  59. Jiang B, Fu X, Yan L, Li S, Zhao D, Wang X, Duan Y, Yan Y, Li E, Wu K, Inglis BM, Ji W, Xu RH, Si W . 6 . Transplantation of human ESC-derived mesenchymal stem cell spheroids ameliorates spontaneous osteoarthritis in rhesus macaques . Theranostics . 9 . 22 . 6587–6600 . 2019 . 31588237 . 6771254 . 10.7150/thno.35391 .
  60. Borzabadi-Farahani A . Effect of low-level laser irradiation on proliferation of human dental mesenchymal stem cells; a systemic review . Journal of Photochemistry and Photobiology. B, Biology . 162 . 577–582 . September 2016 . 27475781 . 10.1016/j.jphotobiol.2016.07.022 .
  61. Becker AJ, McCulloch EA, Till JE . Cytological demonstration of the clonal nature of spleen colonies derived from transplanted mouse marrow cells . Nature . 197 . 4866 . 452–4 . February 1963 . 13970094 . 10.1038/197452a0 . 1963Natur.197..452B . 1807/2779 . 11106827 . free .
  62. Siminovitch L, Mcculloch EA, Till JE . Journal of Cellular and Comparative Physiology . 62 . 3 . 327–36 . December 1963 . 14086156 . 10.1002/jcp.1030620313 . 1807/2778 . The distribution of colony-forming cells among spleen colonies . free .
  63. Caplan AI . Mesenchymal Stem Cells: Time to Change the Name! . Stem Cells Translational Medicine . 6 . 6 . 1445–1451 . June 2017 . 28452204 . 5689741 . 10.1002/sctm.17-0051 .
  64. Friedenstein AJ, Deriglasova UF, Kulagina NN, Panasuk AF, Rudakowa SF, Luriá EA, Ruadkow IA . Precursors for fibroblasts in different populations of hematopoietic cells as detected by the in vitro colony assay method . Experimental Hematology . 2 . 2 . 83–92 . 1974 . 4455512 .
  65. Friedenstein AJ, Gorskaja JF, Kulagina NN . Fibroblast precursors in normal and irradiated mouse hematopoietic organs . Experimental Hematology . 4 . 5 . 267–74 . September 1976 . 976387 .
  66. Lazarus HM, Haynesworth SE, Gerson SL, Rosenthal NS, Caplan AI . Ex vivo expansion and subsequent infusion of human bone marrow-derived stromal progenitor cells (mesenchymal progenitor cells): implications for therapeutic use . Bone Marrow Transplantation . 16 . 4 . 557–564 . October 1995 . 8528172 .
  67. Galipeau J, Sensébé L . Mesenchymal Stromal Cells: Clinical Challenges and Therapeutic Opportunities . Cell Stem Cell . 22 . 6 . 824–833 . June 2018 . 10.1016/j.stem.2018.05.004 . 29859173 . 6434696 .
  68. Lazarus HM, Haynesworth SE, Gerson SL, Caplan AI . Human bone marrow-derived mesenchymal (stromal) progenitor cells (MPCs) cannot be recovered from peripheral blood progenitor cell collections . Journal of Hematotherapy . 6 . 5 . 447–455 . October 1997 . 9368181 . 10.1089/scd.1.1997.6.447 .
  69. Caplan AI . Medicinal signalling cells: they work, so use them . Nature . 566 . 7742 . 39 . February 2019 . 30723355 . 10.1038/d41586-019-00490-6 . free . 2019Natur.566R..39C .
  70. News: Vigdor N . 2021-02-04. Lawmaker Promoted Stem Cell Therapy for Covid-19 in Fraud Scheme, U.S. Says. en-US. The New York Times. 2021-02-08. 0362-4331.
  71. Web site: Office of the Commissioner . 2020-09-09 . FDA Warns About Stem Cell Therapies . U.S. Food and Drug Administration . en .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Mesenchymal stem cell".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.